tiprankstipranks
Protagonist Therapeutics Board and Audit Committee Changes
Company Announcements

Protagonist Therapeutics Board and Audit Committee Changes

Don't Miss our Black Friday Offers:

An update from Protagonist Therapeutics ( (PTGX) ) is now available.

Daniel N. Swisher Jr. has stepped down from his role on the Board of Directors and the Audit Committee of Protagonist Therapeutics, Inc., effective September 17, 2024, with no reported disagreements regarding company operations. He will remain as an advisor to the company. Following his departure, Sarah A. O’Dowd will join the Audit Committee, and the Board will decrease in size from seven to six members.

For an in-depth examination of PTGX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyProtagonist Therapeutics price target raised to $67 from $51 at BTIG
TheFlyProtagonist Therapeutics selects PN-881 as development candidate
TheFlyProtagonist and JNJ say icotrokinra study for PsO meets endpoint
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App